New hope for stem cell patients: safer GVHD prevention on the horizon?
NCT ID NCT04886726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether adding a drug made from urine (uhCG/EGF) to standard therapy can safely prevent graft-versus-host disease (GVHD) in stem cell transplant patients with partially matched donors. About 18 adults with blood cancers who lack a fully matched donor will receive the combination. The main goal is to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henry Ford Hospital
RECRUITINGDetroit, Michigan, 48202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a cancer drug tame graft-versus-host disease when steroids fail?